urmjУральский медицинский журналUral Medical Journal2949-4389Ural State Medical University10.52420/umj.24.4.55JJJTYKurmj-1933Research ArticleОригинальные статьи | Original articlesOriginal articlesОсобенности липидного профиля у пациентов после перенесенной острой тромбоэмболии легочной артерииFeatures of the Lipid Profile in Patients after Acute Pulmonary Embolismhttps://orcid.org/0000-0003-4678-1087ДорохинаК. Р.DorokhinaK. R.

Дорохина Ксения Родионовна — ассистент кафедры госпитальной терапии, институт клинической медицины, УГМУ; кардиолог кардиологического отделения, ЦГБ № 7.

Екатеринбург

Kseniia R. Dorokhina — Assistant of the Department of Hospital Therapy, Institute of Clinical Medicine, Ural State Medical University; Cardiologist of the Cardiology Department, Central City Hospital No. 7.

Ekaterinburg

kd-ds@mail.ruhttps://orcid.org/0000-0003-0763-0542ХромцоваО. М.KhromtsovaO. M.

Хромцова Оксана Михайловна — доктор медицинских наук, доцент, доцент кафедры госпитальной терапии, институт клинической медицины, УГМУ; терапевт терапевтического отделения, ЦГБ № 7.

Екатеринбург

Oksana M. Khromtsova — Doctor of Sciences (Medicine), Associate Professor, Associate Professor of the Department of Hospital Therapy, Institute of Clinical Medicine, Ural State Medical University; Therapist of the Therapeutic Department, Central City Hospital No. 7.

Ekaterinburg

oksanamed@yandex.ruhttps://orcid.org/0000-0001-5906-9895ФоминыхМ. И.FominykhM. I.

Фоминых Мария Игоревна — кандидат медицинских наук, доцент кафедры госпитальной терапии, институт клинической медицины, УГМУ; ревматолог терапевтического отделения, ЦГБ № 7.

Екатеринбург

Maria I. Fominykh — Candidate of Sciences (Medicine), Associate Professor of the Department of Hospital Therapy, Institute of Clinical Medicine, Ural State Medical University; Rheumatologist of the Therapeutic Department, Central City Hospital No. 7.

Ekaterinburg

fominykh_m@mail.ruhttps://orcid.org/0000-0003-4401-2209БожкоЯ. Г.BozhkoY. G.

Божко Яков Григорьевич — кандидат медицинских наук, доцент кафедры поликлинической терапии, институт клинической медицины.

Екатеринбург

Yakov G. Bozhko — Candidate of Sciences (Medicine), Associate Professor of the Department of Polyclinic Therapy, Institute of Clinical Medicine, Ural State Medical University.

Ekaterinburg

yakov-bozhko@ya.ruhttps://orcid.org/0000-0003-2797-1926КудрявцеваЕ. В.KudryavtsevaE. V.

Кудрявцева Елена Владимировна — доктор медицинских наук, доцент, профессор кафедры акушерства и гинекологии.

Екатеринбург

Elena V. Kudryavtseva — Doctor of Sciences (Medicine), Associate Professor, Professor of the Department Obstetrics and Gynecology, Ural Institute of Healthcare Management named after A.B. Blokhin.

Ekaterinburg

elenavladpopova@yandex.ruhttps://orcid.org/0000-0003-0966-9571БазарныйВ. В.BazarnyV. V.

Базарный Владимир Викторович — доктор медицинских наук, профессор, руководитель отдела общей патологии и гистологической лаборатории, центральная научно-исследовательская лаборатория, директор института фундаментальной медицины.

Екатеринбург

Vladimir V. Bazarny — Doctor of Sciences (Medicine), Professor, Head of the Department of General Pathology and Histological Laboratory, Central Research Laboratory, Director of the Institute of Fundamental Medicine, Ural State Medical University.

Ekaterinburg

vlad-bazarny@yandex.ruhttps://orcid.org/0000-0002-4921-7222ПолушинаЛ. Г.PolushinaL. G.

Полушина Лариса Георгиевна — кандидат медицинских наук, заведующий центральной научно-исследовательской лабораторией, институт фундаментальной медицины.

Екатеринбург

Larisa G. Polushina — Candidate of Sciences (Medicine), Head of the Central Research Laboratory, Institute of Fundamental Medicine, Ural State Medical University.

Ekaterinburg

polushina-larisa@bk.ruУральский государственный медицинский университет; Центральная городская больница № 7РоссияUral State Medical University; Central City Hospital No. 7Russian FederationУральский государственный медицинский университетРоссияUral State Medical UniversityRussian FederationУральский институт управления здравоохранением имени А.Б. БлохинаРоссияUral Institute of Healthcare Management named after A.B. BlokhinRussian Federation20252708202524455–66Copyright © Дорохина К.Р., Хромцова О.М., Фоминых М.И., Божко Я.Г., Кудрявцева Е.В., Базарный В.В., Полушина Л.Г., 20252025Дорохина К.Р., Хромцова О.М., Фоминых М.И., Божко Я.Г., Кудрявцева Е.В., Базарный В.В., Полушина Л.Г.Dorokhina K.R., Khromtsova O.M., Fominykh M.I., Bozhko Y.G., Kudryavtseva E.V., Bazarny V.V., Polushina L.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.umjusmu.ru/jour/article/view/1933Введение

Введение. Вопрос о влиянии уровня липидов на риск развития венозных тромбоэмболий (ВТЭ) в настоящее время остается открытым и дискуссионным, в связи с чем изучается влияние дислипидемии на риск развития артериальных и венозных тромбозов.

Цель работы — оценить показатели липидного спектра в крови у пациентов с тромбоэмболией легочной артерии (ТЭЛА) в остром периоде и через 1 год после перенесенного эпизода.

Материалы и методы

Материалы и методы. Проведено проспективное когортное исследование показателей липидного спектра в сыворотке крови: общего холестерина (ОХС), липопротеинов низкой плотности (ХС-ЛПНП), липопротеинов высокой плотности (ХС-ЛПВП), триглицеридов (ТГ), аполипротеинов A1 и B (апоA1 и апоB) у пациентов в остром периоде ТЭЛА и через 1 год наблюдения.

Результаты

Результаты. У пациентов с ТЭЛА в остром периоде отмечается исходно нормальный уровень ОХС, ХС-ЛПНП, ТГ, апоA1, апоB, низкий уровень ХС-ЛПВП в сыворотке крови. Через 1 год наблюдения параметры ОХС, ХС-ЛПНП, ТГ, aпoB сыворотки крови превышают нормальные показатели, выявляется дислипидемия за счет преобладания ХС-ЛПНП, уровень ХС-ЛПВП нормализуется.

Обсуждение

Обсуждение. Определение липидного спектра исходно и в динамике позволяет контролировать изменение концентрации параметров липидного обмена и проводить коррекцию дислипидемии для снижения сердечно-сосудистого риска.

Заключение

Заключение. В остром периоде ТЭЛА отмечаются нормальные уровни ОХС, ХС-ЛПНП, ТГ, aпoA1, aпoB сыворотки крови, но более низкие в сравнении с пациентами без анамнеза ВТЭ, низкий уровень ХС-ЛПВП. Через год наблюдения выявляются гиперхолестеринемия, дислипидемия за счет ХС-ЛПНП, ТГ, апоB, что повышает сердечно-сосудистый риск у пациентов с анамнезом ТЭЛА и требует коррекции.

Introduction

Introduction. The question of the effect of lipids on the risk of venous thromboembolism (VTE) currently remains open and debatable. The effect of dyslipidemia on the risk of arterial and venous thrombosis is currently being studied.

The aim of the work was to evaluate the parameters of the blood lipids of patients with pulmonary embolism (PE) in the acute period and 1 year after the episode.

Materials and methods

Materials and methods. A prospective cohort study of lipids — total cholesterol (TCH), low-density lipoproteins (LDL-C), high-density lipoproteins (HDL-C), triglycerides (TG), apolipoproteins A1and B (ApoA1 and ApoB) — was conducted in patients in the acute period PE and after 1 year of follow-up.

Results

Results. Patients with PE in the acute period have initially normal levels of THC, LDL-C, TG, ApoA1, ApoB, and low levels of HDL-C. After 1 year of follow-up, the levels of THC, LDL-C, TG, and ApoB exceed normal values, dyslipidemia is detected due to the predominance of LDL-C, and HDL-C levels return to normal.

Discussion

Discussion. Determination of the blood lipids initially and over time allows monitoring changes in the concentration of lipids and correcting dyslipidemia to reduce cardiovascular risk.

Conclusion

Conclusion. In the acute period of PE, normal levels of THC, LDL-C, TG, ApoA1, ApoB are noted, but lower in comparison with patients without a history of VTE, low levels of HDL-C. After a year of follow-up, hypercholesterolemia, dyslipidemia due to LDL-C, TG, and ApoB are detected, which creates a cardiovascular risk in these patients and requires correction.

тромбоэмболия легочной артериивенозные тромбоэмболииартериальная гипертензиялипидный спектрвенозные тромбозыpulmonary embolismvenous thromboembolismarterial hypertensionlipid spectrumvenous thrombosisReferencesGarcía Raso A, Ene G, Miranda C, Vidal R, Mata R, Llamas Sillero MP. Association between venous thrombosis and dyslipidemia. Medicina Clinica. 2014;143(1):1–5. DOI: https://doi.org/10.1016/j.medcli.2013.07.024.García Raso A, Ene G, Miranda C, Vidal R, Mata R, Llamas Sillero MP. Association between venous thrombosis and dyslipidemia. Medicina Clinica. 2014;143(1):1–5. DOI: https://doi.org/10.1016/j.medcli.2013.07.024.Robertson L, Broderick C, Yeoh SE, Stansby G. Effect of testing for cancer on cancer — or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE. Cochrane Database of Systematic Reviews. 2021;(10):010837. DOI: https://doi.org/10.1002/14651858.CD010837.pub5.Robertson L, Broderick C, Yeoh SE, Stansby G. Effect of testing for cancer on cancer — or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE. Cochrane Database of Systematic Reviews. 2021;(10):010837. DOI: https://doi.org/10.1002/14651858.CD010837.pub5.Mi Y, Yan S, Lu Y, Liang Y, Li C. Venous thromboembolism has the same risk factors as atherosclerosis: A PRISMA-compliant systemic review and meta-analysis. Medicine. 2016;95(32):4495. DOI: https://doi.org/10.1097/MD.0000000000004495.Mi Y, Yan S, Lu Y, Liang Y, Li C. Venous thromboembolism has the same risk factors as atherosclerosis: A PRISMA-compliant systemic review and meta-analysis. Medicine. 2016;95(32):4495. DOI: https://doi.org/10.1097/MD.0000000000004495.Delluc A, Lacut K, Rodger MA. Arterial and venous thrombosis: What’s the link? A narrative review. Thrombosis Research. 2020;191:97–102. DOI: https://doi.org/10.1016/j.thromres.2020.04.035.Delluc A, Lacut K, Rodger MA. Arterial and venous thrombosis: What’s the link? A narrative review. Thrombosis Research. 2020;191:97–102. DOI: https://doi.org/10.1016/j.thromres.2020.04.035.Zabczyk M, Ariens RA, Undas A. Fibrin clot properties in cardiovascular disease: From basic mechanisms to clinical practice. Cardiovasclular Research. 2023;119(1):94–111. DOI: https://doi.org/10.1093/cvr/cvad017.Zabczyk M, Ariens RA, Undas A. Fibrin clot properties in cardiovascular disease: From basic mechanisms to clinical practice. Cardiovasclular Research. 2023;119(1):94–111. DOI: https://doi.org/10.1093/cvr/cvad017.Lonnberg F, Roos A, Farm M, Heurlin A, Okas M, Gigante B, et al. Causes of death after first time venous thromboembolism. Thrombosis Journal. 2024;22(1):13–16. DOI: https://doi.org/10.1186/s12959-024-00586-8.Lonnberg F, Roos A, Farm M, Heurlin A, Okas M, Gigante B, et al. Causes of death after first time venous thromboembolism. Thrombosis Journal. 2024;22(1):13–16. DOI: https://doi.org/10.1186/s12959-024-00586-8.Kunutsor SK, Mäkikallio TH, Kauhanen J, Voutilainen A, Laukkanen JA. Lipoprotein(a) is not associated with venous thromboembolism risk. Scandinavian Cardiovascular Journal. 2019;53(3):125–132. DOI: https://doi.org/10.1080/14017431.2019.1612087.Kunutsor SK, Mäkikallio TH, Kauhanen J, Voutilainen A, Laukkanen JA. Lipoprotein(a) is not associated with venous thromboembolism risk. Scandinavian Cardiovascular Journal. 2019;53(3):125–132. DOI: https://doi.org/10.1080/14017431.2019.1612087.Kowalski J, Jedrzejczyk JT, Barylski M. Value of D-dimer and HDL cholesterol concentrations in predicting the occurrence of acute pulmonary embolism. Polski Merkuriusz Lekarski. 2016;40(239):283–287. PMID: https://pubmed.gov/27234856.Kowalski J, Jedrzejczyk JT, Barylski M. Value of D-dimer and HDL cholesterol concentrations in predicting the occurrence of acute pulmonary embolism. Polski Merkuriusz Lekarski. 2016;40(239):283–287. PMID: https://pubmed.gov/27234856.Mengjin H, Xiaosong L, Yuejin Y. Causal associations between cardiovascular risk factors and venous thromboembolism. Seminars in Thrombosis and Hemostasis. 2023;49(7):679–687. DOI: https://doi.org/10.1055/s-0042-1760335.Mengjin H, Xiaosong L, Yuejin Y. Causal associations between cardiovascular risk factors and venous thromboembolism. Seminars in Thrombosis and Hemostasis. 2023;49(7):679–687. DOI: https://doi.org/10.1055/s-0042-1760335.Nielsen LB, Moestrup SK. Lipids metabolism: Lipids and lipoproteins — effect on blood clotting and risk of venous thrombosis. Current Opinion in Lipidology. 2006;17(1):89–91. DOI: https://doi.org/10.1097/01.mol.0000199811.23849.38.Nielsen LB, Moestrup SK. Lipids metabolism: Lipids and lipoproteins — effect on blood clotting and risk of venous thrombosis. Current Opinion in Lipidology. 2006;17(1):89–91. DOI: https://doi.org/10.1097/01.mol.0000199811.23849.38.van Schouwenburg IM, Mahmoodi BK, Gansevoort RT, Muntinghe FL, Dullaart RP, Kluin-Nelemans HC, et al. Lipid levels do not influence the risk of venous thromboembolism. Thrombosis and Haemostasis. 2012; 108(5):923–929. DOI: https://doi.org/10.1160/TH12-06-0426.van Schouwenburg IM, Mahmoodi BK, Gansevoort RT, Muntinghe FL, Dullaart RP, Kluin-Nelemans HC, et al. Lipid levels do not influence the risk of venous thromboembolism. Thrombosis and Haemostasis. 2012; 108(5):923–929. DOI: https://doi.org/10.1160/TH12-06-0426.Chen F, Peng D, Xia Y, Sun H, Shen H, Xia M. Identification of oxylipins and lipid mediators in pulmonary embolism. Lipids in Health and Disease. 2024;23(1):325–330. DOI: https://doi.org/10.1186/s12944-024-02315-6.Chen F, Peng D, Xia Y, Sun H, Shen H, Xia M. Identification of oxylipins and lipid mediators in pulmonary embolism. Lipids in Health and Disease. 2024;23(1):325–330. DOI: https://doi.org/10.1186/s12944-024-02315-6.Karataş MB, Güngör B, İpek G, Çanga Y, Günaydın ZY, Onuk T, et al. Association of serum cholesterol levels with short-term mortality in patients with acute pulmonary embolism. Heart, Lung and Circulation. 2016; 25(4):365–370. DOI: https://doi.org/10.1016/j.hlc.2015.09.005.Karataş MB, Güngör B, İpek G, Çanga Y, Günaydın ZY, Onuk T, et al. Association of serum cholesterol levels with short-term mortality in patients with acute pulmonary embolism. Heart, Lung and Circulation. 2016; 25(4):365–370. DOI: https://doi.org/10.1016/j.hlc.2015.09.005.Podlipaeva AA, Mullova IS, Pavlova TV, Ushakova EV, Duplyakov DV. New biological markers for diagnosing and predicting the risk of death in patients with pulmonary embolism. Russian Journal of Cardiology. 2020;25(S4):4202. (In Russ.). DOI: https://doi.org/10.15829/1560-4071-2020-4202.Podlipaeva AA, Mullova IS, Pavlova TV, Ushakova EV, Duplyakov DV. New biological markers for diagnosing and predicting the risk of death in patients with pulmonary embolism. Russian Journal of Cardiology. 2020;25(S4):4202. (In Russ.). DOI: https://doi.org/10.15829/1560-4071-2020-4202.Bryk AH, Natorska J, Ząbczyk M, Zettl K, Wiśniewski JR, Undas A. Plasma fibrin clot proteomics in patients with acute pulmonary embolism: Association with clot properties. Journal of Proteomics. 2020;229:103946. DOI: https://doi.org/10.1016/j.jprot.2020.103946.Bryk AH, Natorska J, Ząbczyk M, Zettl K, Wiśniewski JR, Undas A. Plasma fibrin clot proteomics in patients with acute pulmonary embolism: Association with clot properties. Journal of Proteomics. 2020;229:103946. DOI: https://doi.org/10.1016/j.jprot.2020.103946.Zaccardi F, Kunutsor SK, Seidu S, Davies MJ, Khunti K. Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? Atherosclerosis. 2018;271:223–231. DOI: https://doi.org/10.1016/j.atherosclerosis.2018.02.035.Zaccardi F, Kunutsor SK, Seidu S, Davies MJ, Khunti K. Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? Atherosclerosis. 2018;271:223–231. DOI: https://doi.org/10.1016/j.atherosclerosis.2018.02.035.Goldhaber SZ. Obesity and pulmonary embolism: Can we dismantle the “obesity paradox”. Thrombosis and Haemostasis. 2024;124(1):58–60. DOI: https://doi.org/10.1055/a-2187-0966.Goldhaber SZ. Obesity and pulmonary embolism: Can we dismantle the “obesity paradox”. Thrombosis and Haemostasis. 2024;124(1):58–60. DOI: https://doi.org/10.1055/a-2187-0966.Zhang Z, Rodriguez M, Zheng Z. Clot or not? Reviewing the reciprocal regulation between lipids and blood clotting. Arteriosclerosis, Thrombosis and Vascular Biology. 2024;44(3):533–544. DOI: https://doi.org/10.1161/ATVBAHA.123.318286.Zhang Z, Rodriguez M, Zheng Z. Clot or not? Reviewing the reciprocal regulation between lipids and blood clotting. Arteriosclerosis, Thrombosis and Vascular Biology. 2024;44(3):533–544. DOI: https://doi.org/10.1161/ATVBAHA.123.318286.Belaj K, Hackl G, Rief P, Eller P, Brodmann M, Gary T. Changes in lipid metabolism and extension of venous thromboembolism. Annals of Nutrition and Metabolism. 2014;64(2):122–126. DOI: https://doi.org/10.1159/000360484.Belaj K, Hackl G, Rief P, Eller P, Brodmann M, Gary T. Changes in lipid metabolism and extension of venous thromboembolism. Annals of Nutrition and Metabolism. 2014;64(2):122–126. DOI: https://doi.org/10.1159/000360484.Morelli VM, Lijfering WM, Rosendaal FR, Cannegieter SC. Lipid levels and risk of recurrent venous thrombosis: Results from the MEGA follow-up study. Journal Thrombosis and Haemostasis. 2017;15(4):695–701. DOI: https://doi.org/10.1111/jth.13640.Morelli VM, Lijfering WM, Rosendaal FR, Cannegieter SC. Lipid levels and risk of recurrent venous thrombosis: Results from the MEGA follow-up study. Journal Thrombosis and Haemostasis. 2017;15(4):695–701. DOI: https://doi.org/10.1111/jth.13640.Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation. 2005;112(6):893–899. DOI: https://doi.org/10.1161/CIRCULATIONAHA.104.521344.Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation. 2005;112(6):893–899. DOI: https://doi.org/10.1161/CIRCULATIONAHA.104.521344.Siudut J, Ząbczyk M, Wołkow P, Polak M, Undas A, Jawień J. Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: Association with lipoproteins and C-reactive protein. Vascular Pharmacology. 2022;144:106977. DOI: https://doi.org/10.1016/j.vph.2022.106977.Siudut J, Ząbczyk M, Wołkow P, Polak M, Undas A, Jawień J. Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: Association with lipoproteins and C-reactive protein. Vascular Pharmacology. 2022;144:106977. DOI: https://doi.org/10.1016/j.vph.2022.106977.Labudovic D, Kostovska I, Tosheska Trajkovska K, Cekovska S, Brezovska Kavrakova J, Topuzovska S. Lipoprotein(a) — link between atherogenesis and thrombosis. Prague Medical Report. 2019;120(2–3):39–51. DOI: https://doi.org/10.14712/23362936.2019.9.Labudovic D, Kostovska I, Tosheska Trajkovska K, Cekovska S, Brezovska Kavrakova J, Topuzovska S. Lipoprotein(a) — link between atherogenesis and thrombosis. Prague Medical Report. 2019;120(2–3):39–51. DOI: https://doi.org/10.14712/23362936.2019.9.Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, et al. The effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of venous thromboembolism. Circulation. 2020; 141(20):1600–1607. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.046397.Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, et al. The effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of venous thromboembolism. Circulation. 2020; 141(20):1600–1607. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.046397.Izmozherova NV, Popov AA, Kuryndina AA, Gavrilova EI, Shambatov MA, Bakhtin VM. Analysis of pharmacotherapy of arterial hypertension in multimorbid patients. Ural Medical Journal. 2025;24(1):7–25. (In Russ.). DOI: https://doi.org/10.52420/umj.24.1.7.Izmozherova NV, Popov AA, Kuryndina AA, Gavrilova EI, Shambatov MA, Bakhtin VM. Analysis of pharmacotherapy of arterial hypertension in multimorbid patients. Ural Medical Journal. 2025;24(1):7–25. (In Russ.). DOI: https://doi.org/10.52420/umj.24.1.7.Farmakis IT, Christodoulou KC, Hobohm L, Konstantinides SV, Valerio L. Lipid lowering for prevention of venous thromboembolism: A network meta-analysis. European Heart Journal. 2024;45(35):3219–3227. DOI: https://doi.org/10.1093/eurheartj/ehae361.Farmakis IT, Christodoulou KC, Hobohm L, Konstantinides SV, Valerio L. Lipid lowering for prevention of venous thromboembolism: A network meta-analysis. European Heart Journal. 2024;45(35):3219–3227. DOI: https://doi.org/10.1093/eurheartj/ehae361.

The authors declare that there are no conflicts of interest present.